cumulative probability of success (PoS) from Phase 1 to approval for an oncology drug like Bisantrene might range between measly 10-20%(this is broker estimates and now compare this with azer cell) This considers both historical benchmarks and the specific context of Bisantrene's development
cumulative probability of success (PoS) from Phase 1 to approval...
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5443565 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2171910 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |